SARomics Biostructures' news archive

Latest Newsletters

For older newsletters and other posts please visit our LinkedIn company site

Press releases

SARomics Biostructures, Red Glead Discovery and researchers at Sahlgrenska Cancer Center jointly collaborate in this project that was one of 15 financed by Swelife in order to increase health and well- being as well as increasing the sustainable growth and competitiveness of Swedish life science. In the project, a preclinical innovative epigenetic therapy will be significantly advanced towards clinical studies for an orphan cancer indication. Press release…

Aqilion AB contracts integrated drug discovery project with SARomics Biostructures and Red Glead Discovery. The aim of the project is to develop drug candidates that bind to a target protein that is essential for both malignant disease development and for inflammatory conditions. A successful project can therefore help to develop new medications to treat orphan drug indications in the field of autoinflammatory diseases, as well as new combination therapies within the field of oncology, primarily intestinal cancer. Read more…

SARomics Biostructures will assist Follicum AB to study FOL peptide binding to receptors on pancreatic cells. The new research will broaden the knowledge base within the company's project aimed at the development of a peptide-based treatment for diabetes. The project will study FOL peptide binding to the surface receptors / targets previously identified on pancreatic cells to investigate how this binding results in an increase in insulin secretion at the same time as the pancreatic cells are protected and preserved.. Read more…

SARomics Biostructures and Red Glead Discovery acquire the weak-affinity chromatography (WAC™) technology from Transientic Interactions AB. Press release… (in Swedish)

SARomics Biostructures will use its 3D structure determination capabilities to assist Alligator Bioscience AB, a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, to verify the unique functionality of ATOR-1017, an immuno-stimulatory antibody in development for the treatment of metastatic cancer. Read more…

University of Copenhagen, SARomics Biostructures and Enamine join forces to develop the next generation of safer anti-depressants in an EU-funded project Selective Agonists For Serotonin Receptors (SAFER). Read more… or visit project site SAFER

SARomics Biostructures & Carna Biosciences sign exclusive distribution agreement covering the Japanese market,
Press release…

SARomics Biostructures opens U.S. sales office!
Press release…

SARomics Biostructures and Xbrane Bioscience form a strategic partnership for “off-the-shelf” protein structures,
Press release...

SARomics Biostructures and
BioVersys join efforts to combat multidrug-resistant bacterial infections, Press release...

SARomics Biostructures first Nordic company to obtain growth capital through a collaborative initiative between Sparbanken Öresund and the European Investment Fund,
Press release

SARomics Biostructures coordinates an EU-funded industry-academia drug discovery partnership,
Press release...

SARomics Biostructures and Red Glead Discovery enter lead discovery collaboration in the field of epigenetic disorders,
Press release...

SARomics Biostructures brings in new strategic owners,
Press release...

SARomics Biostructures coordinates KINOMED, Eurostars funded kinase project,
Press release...

Inimex Pharmaceuticals and SARomics Biostructures Announce Successful Achievement of Key Scientific Milestone in Structural Biology Collaboration.
Press release...

UNIZYME Laboratories and SARomics enter into drug discovery collaboration
press release

SARomics and Alligator Bioscience, Lund, have entered into a collaboration agreement. Press Release